Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (18)

Advertisement

Research Article Free access | 10.1172/JCI116010

Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha.

S Isonishi, A P Jekunen, D K Hom, A Eastman, P S Edelstein, F B Thiebaut, R D Christen, and S B Howell

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Isonishi, S. in: PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Jekunen, A. in: PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Hom, D. in: PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Eastman, A. in: PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Edelstein, P. in: PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Thiebaut, F. in: PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Christen, R. in: PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Howell, S. in: PubMed | Google Scholar

Published October 1, 1992 - More info

Published in Volume 90, Issue 4 on October 1, 1992
J Clin Invest. 1992;90(4):1436–1442. https://doi.org/10.1172/JCI116010.
© 1992 The American Society for Clinical Investigation
Published October 1, 1992 - Version history
View PDF
Abstract

A twofold change in the cisplatin (DDP) sensitivity of 2008 human ovarian carcinoma cells is sufficient to reduce tumor response in vivo. The DDP sensitivity of these cells can be enhanced by activation of the epidermal growth factor and protein kinase C signal transduction pathways. We report here that two endogenous growth factors, bombesin and tumor necrosis factor alpha (TNF alpha), enhanced DDP sensitivity by factors of 1.7 +/- 0.1 (SD)-fold and 1.8 +/- 0.1 (SD)-fold, respectively. Both agents also produced sensitization in an 11-fold DDP-resistant 2008 subline. Neither bombesin nor TNF alpha changed the accumulation of DDP, glutathione content, or glutathione-S-transferase activity in 2008 cells. However, a 2-h exposure to both bombesin and TNF alpha was sufficient to increase 2008 cloning efficiency by up to 2.6 +/- 0.1 (SD)-fold and 2.2 +/- 0.1 (SD)-fold, and it increased average colony size by 1.35 +/- 0.1 (SD)-fold and 1.55 +/- 0.1 (SD)-fold, respectively. Bombesin increased intracellular free calcium, and this was blocked by the bombesin receptor-specific antagonist SC196, demonstrating that 2008 cells have functional bombesin receptors. These results indicate that bombesin and TNF alpha can enhance sensitivity to DDP in both DDP sensitive and resistant variants of a human ovarian carcinoma and that both agents serve as growth factors for this tumor.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1436
page 1436
icon of scanned page 1437
page 1437
icon of scanned page 1438
page 1438
icon of scanned page 1439
page 1439
icon of scanned page 1440
page 1440
icon of scanned page 1441
page 1441
icon of scanned page 1442
page 1442
Version history
  • Version 1 (October 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (18)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts